Lonza steps up for GSK and Genmab

Arzerra, the recently approved monoclonal antibody treatment for leukemia from GlaxoSmithKline and Genmab, will be manufactured by Lonza. The Swiss-based contract manufacturer performed process development and cGMP manufacturing services to support the drug's licensure.

According to Lonza, Arzerra treats chronic lymphocytic leukemia by alerting the immune system to protect B-cells, which become cancerous as a result of the disease. The drug attaches to epitope molecules on the cells' surface.

Separately, Lonza has acquired AlgoNomics NV, a Belgium-based provider of immunogenicity screening services and tools. The AlgoNomics Tripole technology platform supports Lonza's aim to incorporate quality by design at the molecular level, improving the manufacturability of protein-based drugs. 

- here's the Arzerra announcement
- read the AlgoNomics release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.